SHANGHAI, China I March 23, 2025 I Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, ...
MHC-I upregulation by macbecin II in the solid tumors potentiates the effect of active immunotherapy
We aimed to restore MHC-I expression on the surface of solid tumors including breast cancer and melanoma cells to regain sensitivity to immunotherapy and suppress metastatic progression. We screened a ...
The success of any transplant depends on cells expressing the major histocompatibility complex (both MHC class I and class II) - a group of proteins involved with the immune response to reject a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback